Concord Biotech’s stock announced the success of the Russian GMP (Good Manufacturing Practice) inspection in its active pharmaceutical ingredient (API) manufacturing facility located in Dholka, Gujarat. The inspection lasted from July 22, 2025 to 25 July, 2025.
The company said that this achievement reflects its commitment to maintain quality, safety and high standards of regulatory compliance. It also shows the company’s attention on meeting the needs of global regulatory authorities.
The announcement was made on 26 July 2025 and is signed by Concord Biotech company Secretary and Compliance Officer Hina Ronak Patel.